Subscribe and never miss the next wave: References [3] Expo West 2026 live: Givaudan presents personalized beverages, GLP-1 insights & digital aroma tech
Neuroscience, 180, 111121
Then, we selected a cohort of patients without CeD taking AOMs from our previously existing database, that were matched by sex and AOM (phentermine, phentermine-topiramate, liraglutide, low-dose semaglutide, high-dose semaglutide), on a 2:1 ratio to the group with CeD
or exploring self-pay options including the NovoCare self-pay program or compounded semaglutide through a telehealth provider
Theres not much preliminary data that makes me worried
GLP-1 agonists are a class of medications initially developed to treat type 2 diabetes that have since proven highly effective for weight loss